Platform

Treating disease by targeting the cell state.

Our novel platform enables cell state-correcting drug discovery to solve complex diseases.

 

By integrating multi-omics to map complex intercellular interactions, our AI-driven platform contextualizes disease biology and predicts chemical interventions to revert cell dysfunction at the optimal time to restore healthy function.

Supported by human in-vitro modeling and data to increase clinical translatability, our next-generation chemistry engine delivers novel, orally available chemical compounds with superior efficacy and safety.

Multi-omics visualizes the complex interplay of disease mechanisms and gene networks at single-cell resolution.

Our target: the dynamic cell state

Conventional drug discovery narrows down disease to a single target to define and deliver therapeutic interventions, but often this approach is insufficient because disease phenotypes are based on a cascade of complex cellular relationships and interactions that occur at specific times in the cell development process.

Focusing on therapeutic intervention within this dynamic disease state, our goal is to deliver novel therapeutics that switch disease mechanisms to healthy cell function.

Our platform harnesses high-dimensional transcriptomics to map and contextualize disease biology at the single-cell level. This comprehensive view allows us to decode dysregulated networks and target them effectively.

AI-enabled modeling is trained on the dynamic cell state to predict chemical structures that can precisely switch disease cell states.

Biologically relevant AI predictions

Our single-cell foundation models learn and understand the language of disease mechanisms and relationships with chemistry to predict chemical interventions that can modulate dynamic cell states. In doing so, we can switch key mechanisms in the cell state to restore proper function.

Our integrated “lab-in-the-loop” methodology enables efficient drug discovery processes to deliver promising novel chemical entities. This iterative framework improves both the efficacy and safety profile of selected compounds through continuous optimization and advanced evaluation in human-relevant models.

The result: Cell state-correcting therapies

With the combined power of deep transcriptomics and AI-driven predictive modeling, our platform engineers new therapies that can precisely, effectively and safely address dysfunctional cell states.

Our goal: To create best-in-class medicines in accessible oral formats to solve some of today’s most challenging and complex diseases.

Already, the platform is demonstrating its potential with our first cell state-correcting candidate now entering clinical studies.